Degarelix Research: What 402 Studies Show (2026) | RetatrutideCompare

Degarelix — 402 studies indexed on PubMed. Long-acting GnRH antagonist providing immediate testosterone suppression in prostate cancer without flare. Half-life: ~53 days (depot at 240 mg). FDA status: FDA-approved (2008).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Degarelix?

There are approximately 402 studies indexed on PubMed that mention Degarelix (Firmagon, FE-200486), based on a search last updated 2026-06-18.

Is Degarelix FDA-approved?

FDA status: FDA-approved (2008).

How does Degarelix work?

Long-acting GnRH antagonist providing immediate testosterone suppression in prostate cancer without flare.

Reference facts

Also known as: Firmagon, FE-200486
Category: GnRH & Reproductive
Mechanism of action: Long-acting GnRH antagonist providing immediate testosterone suppression in prostate cancer without flare.
Targets: GnRH receptor (antagonist)
Indications under research or approved: Advanced prostate cancer
Regulatory status (reference entry): FDA-approved (2008)
Half-life: ~53 days (depot at 240 mg)
Sequence notes: Decapeptide GnRH antagonist Ac-D-2Nal-D-4ClPhe-D-3Pal-Ser-4Aph(L-Hor)-D-4Aph(Cbm)-Leu-ILys-Pro-D-Ala-NH2.
Molecular weight (Da): 1632
Originator / sponsor: Ferring Pharmaceuticals
First reported: 2002

Primary References

Firmagon FDA label

Explore research articles about Degarelix

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.